{
  "resourceType" : "Procedure",
  "id" : "Fall2-Systemtherapie-Adjuvant",
  "meta" : {
    "profile" : ["https://www.senologie.org/fhir/StructureDefinition/senologie-systemtherapie-procedure"]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Procedure Fall2-Systemtherapie-Adjuvant</b></p><a name=\"Fall2-Systemtherapie-Adjuvant\"> </a><a name=\"hcFall2-Systemtherapie-Adjuvant\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-senologie-systemtherapie-procedure.html\">BIH Senologie Systemtherapie (übergeordnet)</a></p></div><p><b>MII EX Onko Systemische Therapie Intention</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-intention K}\">kurativ</span></p><p><b>status</b>: Completed</p><p><b>category</b>: <span title=\"Codes:{http://snomed.info/sct 18629005}\">Administration of medication</span></p><p><b>code</b>: <span title=\"Codes:{http://fhir.de/CodeSystem/bfarm/ops 8-547.32}\">Immuntherapie mit monoklonalen Antikörpern: PD-1-Antikörper</span></p><p><b>subject</b>: <a href=\"Patient-Fall2-Patient-Lena-Hoffmann.html\">Lena Hoffmann  Female, DoB: 1980-09-28 ( http://fhir.bih-charite.de/sid/patient-id#SENO-2025-002)</a></p><p><b>performed</b>: 2025-10-01 --&gt; 2026-07-01</p><p><b>reasonReference</b>: <a href=\"Condition-Fall2-Diagnose-Mammakarzinom.html\">Condition Malignant neoplasm of breast</a></p><p><b>outcome</b>: <span title=\"Codes:{https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-ende-grund P}\">Pembrolizumab Maintenance für 9 Zyklen, dann Abbruch wegen Progression</span></p><p><b>usedCode</b>: <span title=\"Codes:{http://snomed.info/sct 716125002}\">Pembrolizumab 200 mg q3w, adjuvant Maintenance</span></p></div>"
  },
  "extension" : [{
    "url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-ex-onko-systemische-therapie-intention",
    "valueCodeableConcept" : {
      "coding" : [{
        "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-intention",
        "code" : "K",
        "display" : "kurativ"
      }]
    }
  }],
  "status" : "completed",
  "category" : {
    "coding" : [{
      "system" : "http://snomed.info/sct",
      "code" : "18629005",
      "display" : "Administration of medication"
    }]
  },
  "code" : {
    "coding" : [{
      "system" : "http://fhir.de/CodeSystem/bfarm/ops",
      "version" : "2025",
      "code" : "8-547.32",
      "display" : "Immuntherapie mit monoklonalen Antikörpern: PD-1-Antikörper"
    }]
  },
  "subject" : {
    "reference" : "Patient/Fall2-Patient-Lena-Hoffmann"
  },
  "performedPeriod" : {
    "start" : "2025-10-01",
    "end" : "2026-07-01"
  },
  "reasonReference" : [{
    "reference" : "Condition/Fall2-Diagnose-Mammakarzinom"
  }],
  "outcome" : {
    "coding" : [{
      "system" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-ende-grund",
      "code" : "P",
      "display" : "Abbruch wegen Progress"
    }],
    "text" : "Pembrolizumab Maintenance für 9 Zyklen, dann Abbruch wegen Progression"
  },
  "usedCode" : [{
    "coding" : [{
      "system" : "http://snomed.info/sct",
      "code" : "716125002",
      "display" : "Pembrolizumab"
    }],
    "text" : "Pembrolizumab 200 mg q3w, adjuvant Maintenance"
  }]
}